Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The signals from Dendreon in September last year were that it would take the company until at least the end of 2011 to be able to “ramp up” to full manufacturing capacity for its prostate cancer immunotherapeutic agent, sipuleucel-T (Provenge), even if the FDA does approve this product in May or June of 2010 — [...]
Filed under: Drugs in development | Tagged: Dendreon, Provenge, sipuleucel-T | Leave a Comment »
OK … so here are the results we have all been waiting for for the past few weeks — the data from the IMPACT trial comparing the survival of patients treated with three doses of sipuleucel-T (Provenge) to placebo in men with androgen-independent prostate cancer.
Filed under: Drugs in development | Tagged: androgen-independent prostate cancer, Dendreon, Provenge, sipuleucel-T | 2 Comments »
Dendreon has previously announced that the results of the IMPACT trial will be presented at the annual meeting of the American Urological Association at approximately 2:20 pm on Tuesday, April 28. The company has now announced that, in addition, it will hold a webcast conference call at 4:30 pm CT (5:30 pm ET, 2:30 pm [...]
Filed under: Drugs in development | Tagged: Dendreon, Provenge, sipleucel-T | Comments Off
OK folks … please don’t shoot the messenger … I do not agree with the suggestions about the need for another trial in an article published today by the Financial Times. However, I would be a pretty poor reporter if I didn’t let you know this article is out there in a major international newspaper! [...]
Filed under: Drugs in development | Tagged: Dendreon, Provenge | 3 Comments »
For those who have come to the world of prostate cancer in the past 2 years or so, we recommend that, before you attempt to understand whatever happens on the day that Dendreon announces the results of the Phase III (IMPACT) trial of sipleucel-T, a.k.a. Provenge (expected some time this month), you read the well-constructed [...]
Filed under: Drugs in development | Tagged: Dendreon, Provenge | 2 Comments »
The “New” Prostate Cancer InfoLink has seen a couple of statements from members of the financial community in the last few days that could mislead the unwary into believing that Dendreon’s investigational immunotherapeutic agent, sipuleucel-T (Provenge), has already demonstrated a statistically significant survival benefit in its most recent Phase III clinical trial (the IMPACT trial)
Filed under: Drugs in development | Tagged: Dendreon, Provenge, sipuleucel-T | 1 Comment »
In additional news breaking today: Dendreon Corp. is predicting interim results of the IMPACT study of Provenge in metastatic, androgen-independent prostate cancer by October 2008 The FDA has refused to approve an experimental, topical treatment for erectile dysfunction
Filed under: Drugs in development, Management, Treatment | Tagged: cancer vaccine, Dendreon, ED, erectile dysfunction, hormone, NexMed, prostate, Provenge, refractory | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site